AstraZeneca: 'exceptional' commercial execution in Q3
(CercleFinance.com) - AstraZeneca said on Thursday that it is on track to deliver its full-year 2018 guidance following an "exceptional" commercial execution in the third quarter, which has enabled the drugmaker to return to sales growth.
The group reported third-quarter operating profit that is down 26% at 851 million dollars on total revenues that fell 14% to 5.3 billion dollars.
However, product sales increased by 4%, with new medicines including the cancer drugs Tagrisso, Imfinzi and Lynparza showing "great promise."
"Core" EPS - excluding restructuring costs and charges - fell by 37% to 1.88 dollar.
The Anglo-Swedish group said it expected FY a low single-digit percentage increase in product sales and core EPS of between 3.30 dollars and 3.50 dollars.
The London-listed shares are currently trading up 2% at 5,976 pence after these results.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The group reported third-quarter operating profit that is down 26% at 851 million dollars on total revenues that fell 14% to 5.3 billion dollars.
However, product sales increased by 4%, with new medicines including the cancer drugs Tagrisso, Imfinzi and Lynparza showing "great promise."
"Core" EPS - excluding restructuring costs and charges - fell by 37% to 1.88 dollar.
The Anglo-Swedish group said it expected FY a low single-digit percentage increase in product sales and core EPS of between 3.30 dollars and 3.50 dollars.
The London-listed shares are currently trading up 2% at 5,976 pence after these results.
Copyright (c) 2018 CercleFinance.com. All rights reserved.